A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan

Purpose

The aim of this study is to assess treatment patterns, characteristics, and clinical outcomes among adults with metastatic castration-resistant prostate cancer (mCRPC) who have previously received ≥1 androgen receptor pathway inhibitor (ARPI), ≥1 taxane, and 177Lu-PSMA-617 in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Condition

  • Prostatic Neoplasms, Castration-Resistant

Eligibility

Eligible Ages
Between 18 Years and 115 Years
Eligible Sex
Male
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Evidence of 177Lu-PSMA-617 use on or after 01 January 2021. - Evidence of treatment with ≥1 ARPI, before 177Lu-PSMA-617. - Evidence of treatment with ≥1 taxane, before or after 177Lu-PSMA-617. - Diagnosis of mCRPC prior to or on the index date. The index date is the date of the last treatment administration of the latest of an ARPI, taxane, and 177Lu-PSMA-617. - Age ≥18 years at index.

Exclusion Criteria

• None.

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Arm Groups

ArmDescriptionAssigned Intervention
Overall mCRPC Cohort Adult patients with a diagnosis of mCRPC and evidence of prior treatment with ≥1 ARPI, ≥1 taxane, and 177Lu-PSMA-617 in PRECISION.
mCRPC Progression Subgroup A subgroup of the Overall mCRPC Cohort. Patients with evidence of progression on or after 177Lu-PSMA-617 treatment.
≥1 Subsequent Systemic Therapy Subgroup A subgroup of the Overall mCRPC Cohort. Patients who initiate ≥1 post-index systemic therapy.

Recruiting Locations

Novartis
East Hanover, New Jersey 07936

More Details

Status
Recruiting
Sponsor
Novartis Pharmaceuticals

Study Contact

Novartis Pharmaceuticals
+41613241111
novartis.email@novartis.com